MA34464B1 - Procede pour la preparation de formes enantiomeres de derives d'acide 2,3- diaminopropionique - Google Patents
Procede pour la preparation de formes enantiomeres de derives d'acide 2,3- diaminopropioniqueInfo
- Publication number
- MA34464B1 MA34464B1 MA35657A MA35657A MA34464B1 MA 34464 B1 MA34464 B1 MA 34464B1 MA 35657 A MA35657 A MA 35657A MA 35657 A MA35657 A MA 35657A MA 34464 B1 MA34464 B1 MA 34464B1
- Authority
- MA
- Morocco
- Prior art keywords
- preparation
- acid derivatives
- diaminopropionic acid
- separation
- enantiomer forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
L'invention concerne un procédé pour la préparation des formes énantiomères de dérivés d'acide 2,3-diaminopropionique de formule (I), où R1, R2 et R3 sont définis comme décrit dans les revendications, par séparation d'un racémique. La séparation du racémique en ses énantiomères est effectuée par formation de sels diastéréoisomères après ajout d'un adjuvant énantiomère pur, et ensuite séparation par cristallisation fractionnée.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10305884 | 2010-08-12 | ||
US201061428336P | 2010-12-30 | 2010-12-30 | |
PCT/EP2011/063504 WO2012019967A1 (fr) | 2010-08-12 | 2011-08-05 | Procédé pour la préparation de formes énantiomères de dérivés d'acide 2,3-diaminopropionique |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34464B1 true MA34464B1 (fr) | 2013-08-01 |
Family
ID=43598042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35657A MA34464B1 (fr) | 2010-08-12 | 2011-08-05 | Procede pour la preparation de formes enantiomeres de derives d'acide 2,3- diaminopropionique |
Country Status (23)
Country | Link |
---|---|
US (2) | US8877926B2 (fr) |
EP (1) | EP2603491B1 (fr) |
JP (1) | JP6000248B2 (fr) |
KR (1) | KR20130099044A (fr) |
CN (1) | CN103209961A (fr) |
AR (1) | AR082621A1 (fr) |
AU (1) | AU2011288533A1 (fr) |
BR (1) | BR112013002985A2 (fr) |
CA (1) | CA2807979A1 (fr) |
CL (1) | CL2013000420A1 (fr) |
CO (1) | CO6690757A2 (fr) |
CR (1) | CR20130059A (fr) |
DO (1) | DOP2013000035A (fr) |
EC (1) | ECSP13012434A (fr) |
GT (1) | GT201300038A (fr) |
MA (1) | MA34464B1 (fr) |
MX (1) | MX2013001647A (fr) |
PE (1) | PE20131326A1 (fr) |
RU (1) | RU2013110525A (fr) |
SG (1) | SG187791A1 (fr) |
TW (1) | TW201221504A (fr) |
UY (1) | UY33552A (fr) |
WO (1) | WO2012019967A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2631320C2 (ru) | 2011-12-06 | 2017-09-21 | Санофи | Кристаллические формы [(s)-1-карбамоил-2-(фенилпиримидин-2-иламино)этил]амида 2-(2-метиламинопиримидин-4-ил)-1н-индол-5-карбоновой кислоты |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19850301A1 (de) * | 1998-10-30 | 2000-05-04 | Basf Ag | Verfahren zur Racematspaltung von 2-Hydroxypropionsäuren |
DE19951360A1 (de) | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituierte Indole |
US7462638B2 (en) | 2002-08-17 | 2008-12-09 | Sanofi-Aventis Deutschland Gmbh | Use of IκB-kinase inhibitors in pain therapy |
DE10237722A1 (de) | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
DE102004033406A1 (de) * | 2004-07-10 | 2006-02-16 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten |
US20070142417A1 (en) * | 2005-05-11 | 2007-06-21 | Aventis Pharmaceuticals Inc | Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor |
DE102005025225A1 (de) | 2005-06-01 | 2006-12-07 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten |
-
2011
- 2011-08-05 PE PE2013000263A patent/PE20131326A1/es not_active Application Discontinuation
- 2011-08-05 EP EP11743050.4A patent/EP2603491B1/fr active Active
- 2011-08-05 SG SG2013009899A patent/SG187791A1/en unknown
- 2011-08-05 AU AU2011288533A patent/AU2011288533A1/en not_active Abandoned
- 2011-08-05 MA MA35657A patent/MA34464B1/fr unknown
- 2011-08-05 CA CA2807979A patent/CA2807979A1/fr not_active Abandoned
- 2011-08-05 KR KR1020137006179A patent/KR20130099044A/ko not_active Application Discontinuation
- 2011-08-05 MX MX2013001647A patent/MX2013001647A/es unknown
- 2011-08-05 JP JP2013523574A patent/JP6000248B2/ja active Active
- 2011-08-05 CN CN2011800493516A patent/CN103209961A/zh active Pending
- 2011-08-05 WO PCT/EP2011/063504 patent/WO2012019967A1/fr active Application Filing
- 2011-08-05 BR BR112013002985A patent/BR112013002985A2/pt not_active IP Right Cessation
- 2011-08-05 RU RU2013110525/04A patent/RU2013110525A/ru not_active Application Discontinuation
- 2011-08-10 TW TW100128464A patent/TW201221504A/zh unknown
- 2011-08-10 UY UY0001033552A patent/UY33552A/es not_active Application Discontinuation
- 2011-08-10 AR ARP110102908A patent/AR082621A1/es unknown
-
2013
- 2013-02-08 EC ECSP13012434 patent/ECSP13012434A/es unknown
- 2013-02-11 CR CR20130059A patent/CR20130059A/es unknown
- 2013-02-11 GT GT201300038A patent/GT201300038A/es unknown
- 2013-02-11 CL CL2013000420A patent/CL2013000420A1/es unknown
- 2013-02-11 DO DO2013000035A patent/DOP2013000035A/es unknown
- 2013-02-11 US US13/763,975 patent/US8877926B2/en active Active
- 2013-03-08 CO CO13046970A patent/CO6690757A2/es unknown
-
2014
- 2014-09-30 US US14/502,141 patent/US9434696B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ECSP13012434A (es) | 2013-03-28 |
AR082621A1 (es) | 2012-12-19 |
CN103209961A (zh) | 2013-07-17 |
MX2013001647A (es) | 2013-03-21 |
AU2011288533A1 (en) | 2013-02-28 |
CR20130059A (es) | 2013-03-25 |
CO6690757A2 (es) | 2013-06-17 |
CA2807979A1 (fr) | 2012-02-16 |
US8877926B2 (en) | 2014-11-04 |
US20130211085A1 (en) | 2013-08-15 |
GT201300038A (es) | 2015-06-24 |
DOP2013000035A (es) | 2013-03-15 |
SG187791A1 (en) | 2013-03-28 |
RU2013110525A (ru) | 2014-09-20 |
BR112013002985A2 (pt) | 2017-11-07 |
KR20130099044A (ko) | 2013-09-05 |
UY33552A (es) | 2012-03-30 |
CL2013000420A1 (es) | 2013-04-05 |
WO2012019967A1 (fr) | 2012-02-16 |
US9434696B2 (en) | 2016-09-06 |
PE20131326A1 (es) | 2013-11-12 |
TW201221504A (en) | 2012-06-01 |
EP2603491B1 (fr) | 2014-09-24 |
EP2603491A1 (fr) | 2013-06-19 |
JP6000248B2 (ja) | 2016-09-28 |
US20150018554A1 (en) | 2015-01-15 |
JP2013533296A (ja) | 2013-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GEP20125621B (en) | 3-aminocarbazole compound, pharmaceutical composition containing it and preparation method therefor | |
JP5683761B1 (ja) | 光学活性な二環性γ−アミノ酸誘導体の製造方法 | |
JP5595404B2 (ja) | 光学活性(s)−(−)−2−(n−プロピルアミノ)−5−メトキシテトラリン及び(s)−(−)−2−(n−プロピルアミノ)−5−ヒドロキシテトラリン化合物の調製の方法 | |
JP2009509958A (ja) | ナフチルアルキルアミンによるα−(フェノキシ)フェニル酢酸誘導体の分割 | |
AU2011222644A1 (en) | Improved resolution methods for isolating desired enantiomers of tapentadol intermediates and use thereof for the preparation of tapentadol | |
JPH10507464A (ja) | レボブピバカインとその類似体の晶出 | |
EA201291116A1 (ru) | Способ получения метансульфонатных солей ралфинамида или их r-энантиомеров | |
US8877941B2 (en) | Process for the resolution of medetomidine and recovery of the unwanted enantiomer | |
MA34464B1 (fr) | Procede pour la preparation de formes enantiomeres de derives d'acide 2,3- diaminopropionique | |
JP2013245215A (ja) | 不斉環化反応による光学活性二環性化合物の製造方法 | |
JP4184260B2 (ja) | (r)−(−)−2−ヒドロキシ−2−(2−クロロフェニル)酢酸の分割方法 | |
CN104557677A (zh) | 光学纯的2-哌啶甲酸的化学拆分制备法 | |
KR101304640B1 (ko) | 신규의 로수바스타틴 엔-메틸벤질아민 염 및 그의 제조방법 | |
KR20120133774A (ko) | 키랄 팔라듐 촉매를 이용한 베타-인돌릴 에스테르 화합물의 제조방법 | |
FR3054218B1 (fr) | Procede de dedoublement de sels de baclofene | |
JP2007513936A (ja) | ネフォパムの分割のための方法 | |
WO2012070896A3 (fr) | Procédé de synthèse d'un acide 2,2'-dihydroxy-1,1'-binaphtyl-3-carboxylique énantiomériquement pur | |
JP4126921B2 (ja) | 光学活性なβ−フェニルアラニン誘導体の製造方法 | |
JP6234999B2 (ja) | 光学的に活性な3,3−ジフェニルプロピルアミンを調製するための方法 | |
EA036157B1 (ru) | Способ синтеза промежуточных соединений небиволола | |
KR20070110510A (ko) | 엔안티오퓨어 e-(2s)-알킬-5-할로펜트-4-엔산 및 그에스테르의 제조방법 | |
MX2019015095A (es) | Metodo de sintesis para producir compuestos de cis-imidazolina enantiomericamente puros para uso farmaceutico. | |
MA35509B1 (fr) | Procede de synthese de derives de la 7,8-dimethoxy-1,3-dihydro-2h-3-benzazepin-2-one et application a la synthese de l'ivabradine. | |
JP3828197B2 (ja) | 光学活性3−(p−メトキシフェニル)グリシッド酸アルカリ金属塩の製造法 | |
MX356686B (es) | Procesos e intermediarios para la preparación de un inhibidor macrocíclico de la proteasa del virus de la hepatitis c. |